Relationship between immunometabolic status and cognitive performance among major depression disorder patients

• DOI: 10.1016/j.psyneuen.2021.105631
• Publication Date: 2021-12-16T02:28:02Z
• Authors: Yolanda Sánchez-C...; Alejandro de la T...; Maria J. Portella; Itziar Leal-Leturia; Neus Salvat-Pujol; Clara Massaneda; Aida de Arriba-Arnau; Mikel Urretavizcaya; Mar Peretó; Alba Toll; Antonio Martínez-...; Raquel Ferreiros-...; Pilar Álvarez; Virginia Soria; Pilar López-García
• Keywords: Depression

Alterations in cognitive performance have been described patients with major depressive disorder (MDD). However, the specific risk factors of these changes are not yet known. This study aimed to explore whether inmunometabolic parameters related MDD comparison healthy controls (HC) METHODS: Sample consisted 84 and 78 HC. Both groups were compared on results measured Cambridge Neuropsychological Test Automated Battery (CANTAB), presence metabolic syndrome (MetS) an inflammatory/oxidative index calculated by a principal component analysis peripheral biomarkers (tumor necrosis factor, C-reactive protein 4-hydroxynonenal). A multiple linear regression was carried out, relationship between variables global performance, being latter dependent variable.Significant differences obtained both (F(1157)= 12.93; p < .001), also 56.75; .001). The covariate model (i.e., condition (HC/MDD), sex, age medication loading, MetS, interaction MetS index) statistically significant (F(7157)= 11.24; .01) explained 31% variance. condition, either or HD, (B=-0.97; (B=-0.28; .001) (B=-0.38; = .02) associated performance.Sample size relatively small. cross-sectional design limits possibilities analysis.Our provide evidence conjoint influence inflammatory dysregulation dysfunction patients. In this way, our opens line research immunometabolic agents deal decline MDD.